$IDRA $3.37 called 8/21/13 $1.69 http://www.
Post# of 87
Posted On: 04/22/2014 11:05:19 AM
$IDRA $3.37
called 8/21/13 $1.69
WebSite
Nasdaq
Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor
Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic
MYD88 L265P Mutation
4/7/2014 4:05:00 PM - Business Wire
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings
and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
4/4/2014 8:00:00 AM - PR Newswire
Idera Soars on Phase II Drug Data - Analyst Blog
3/31/2014 5:06:01 PM - Zacks.com
Idera Pharma Reports Positive Top-line Data From Phase 2 Trial Of IMO-8400
3/28/2014 7:30:00 AM - RTT News
Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
3/28/2014 7:15:00 AM - Business Wire
10-K
3/13/14
O/S shares 82,360,165
Last trades
StockWatch
% Opinion
called 8/21/13 $1.69
WebSite
Nasdaq
Idera Presents Preclinical Data at AACR Showing IMO-8400 Inhibits Tumor
Growth and Survival Signaling in B-cell Lymphoma Cells with Oncogenic
MYD88 L265P Mutation
4/7/2014 4:05:00 PM - Business Wire
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings
and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
4/4/2014 8:00:00 AM - PR Newswire
Idera Soars on Phase II Drug Data - Analyst Blog
3/31/2014 5:06:01 PM - Zacks.com
Idera Pharma Reports Positive Top-line Data From Phase 2 Trial Of IMO-8400
3/28/2014 7:30:00 AM - RTT News
Idera Pharmaceuticals Announces Positive Top-line Data in Phase 2 Trial of IMO-8400
3/28/2014 7:15:00 AM - Business Wire
10-K
3/13/14
O/S shares 82,360,165
Last trades
StockWatch
% Opinion
(0)
(0)